Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany
Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany.
BMJ Open Diabetes Res Care. 2021 Apr;9(1). doi: 10.1136/bmjdrc-2020-001848.
Studies have shown beneficial effects of real-time continuous glucose monitoring (rtCGM) usage on clinical outcomes. The objective of this analysis was to identify which therapy adjustments were made by people with type 1 diabetes with impaired hypoglycemia awareness during rtCGM usage enabling reductions in the number of low glucose events observed in the HypoDE (Hypoglycemia in Deutschland) study.
In the multicenter randomized controlled trial in people with type 1 diabetes on multiple daily injections with impaired hypoglycemia awareness, participants recorded their diabetes therapy in 7-day logbooks at baseline and at 6-month follow-up. They used rtCGM or self-monitoring of blood glucose for therapy adjustments. This mechanistic analysis looked at changes in various aspects of therapy.
Logbooks were completed by 70 participants in the rtCGM group and 65 participants in the control group. Participants in the rtCGM group kept their total carbohydrate consumption, daily insulin doses and distribution constant during the study. However, they reported an increased intake of rescue carbohydrates (0.8±0.6 (mean±SD) vs 1.0±0.8 intake/day; baseline-adjusted between-group difference 0.3 intake (0.1-0.5), p=0.031). The glucose threshold at which rescue carbohydrate intake was initiated was elevated from 71±13 mg/dL (3.9±0.7 mmol/L) to 79±14 mg/dL (4.4±0.8 mmol/L) (adjusted between-group difference +7.6 mg/dL (2.4-12.8) (+0.4 mmol/L (0.1-0.7)); p=0.005) in the rtCGM group. Regression analysis showed that follow-up low glucose events were associated with group allocation (p<0.001), low glucose events at baseline (p=0.016) and rescue threshold (p=0.001).
No major adjustments in insulin therapy were made by study participants with impaired hypoglycemia awareness; however, they were more active in preventing hypoglycemia by taking rescue carbohydrates earlier and more often.
NCT02671968.
研究表明实时连续血糖监测(rtCGM)的使用对临床结果有有益影响。本分析的目的是确定在 rtCGM 使用期间,低血糖感知受损的 1 型糖尿病患者进行了哪些治疗调整,从而减少 HypoDE(德国低血糖)研究中观察到的低血糖事件次数。
在低血糖感知受损的 1 型糖尿病患者多针多次注射的多中心随机对照试验中,参与者在基线和 6 个月随访时使用 7 天日志记录他们的糖尿病治疗情况。他们使用 rtCGM 或自我监测血糖来调整治疗。这项机制分析着眼于治疗各个方面的变化。
rtCGM 组有 70 名参与者和对照组有 65 名参与者完成了日志记录。rtCGM 组的参与者在研究期间保持总碳水化合物摄入量、每日胰岛素剂量和分布不变。然而,他们报告说增加了救援碳水化合物的摄入(0.8±0.6(均值±标准差)与 1.0±0.8 摄入/天;组间差异 0.3 摄入(0.1-0.5),p=0.031)。启动救援碳水化合物摄入的血糖阈值从 71±13mg/dL(3.9±0.7mmol/L)升高到 79±14mg/dL(4.4±0.8mmol/L)(组间差异调整+7.6mg/dL(2.4-12.8)(+0.4mmol/L(0.1-0.7));p=0.005)在 rtCGM 组中。回归分析表明,随访时的低血糖事件与分组(p<0.001)、基线时的低血糖事件(p=0.016)和救援阈值(p=0.001)相关。
低血糖感知受损的研究参与者没有对胰岛素治疗进行重大调整;然而,他们通过更早、更频繁地使用救援碳水化合物来更积极地预防低血糖。
NCT02671968。